During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

Scientists engineered T cells to protect instead of kill, potentially enabling targeted treatments for autoimmune disease and ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent ...

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

In the wake of novel bispecific and chimeric antigen receptor T-cell therapies for various cancers, geography still plays a big role in patients' abilities to receive such treatments.

A patient has achieved over 18 years of remission from neuroblastoma, a type of nerve cell cancer, following treatment with ...

Dr Annalisa Morgan previews discussions on disease-modifying therapies, emerging treatments such as CAR T-cell therapy, and ...

CAR-T cell therapy achieves 18-year survival milestone in cancer patient Innovative cancer treatment shows promise as ...

Steve Pruisner walked 110 miles, step by step during his on the adult stem cell transplant unit at University of Iowa Health ...

Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...

The US researchers at the Baylor College of Medicine, Texas Children’s Hospital have said the follow-up observations mark the ...